Bionano Genomics Announces Participation at the American Association for Cancer Research Annual Meeting Spotlighting Optical Genome Mapping Applications and Enhanced NxClinical Capabilities for Cancer Research
- Bionano will exhibit all of its solutions relevant to cancer research: OGM systems, NxClinical software and expert laboratory services
Exhibitor Theater presentation will share the latest OGM research on comprehensive genomic structural variation and homologous recombination deficiency (HRD) analysis from tumor biopsies- Three scientific poster presentations will illustrate the application of Bionano’s OGM in hematological disease, cell line characterization and angiosarcoma
- Bionano will introduce NxClinical version 6.2, which will include powerful capabilities for analysis of homologous recombination deficiency (HRD)
AACR conference sessions will take place
As part of a featured spotlight talk, two cancer genomics experts will share their latest research in comprehensive genomic structural variation and HRD analysis of tumor biopsies, which included OGM and NGS. Dr.
In addition, three posters featuring results from OGM applications will be presented at the conference. The full content of the posters will be made available on the
Poster | Title | Authors | Presented |
5783 | Novel genomic structural variations in angiosarcomas | ||
2931 | Optical genome mapping workflow for identification and annotation of variants in hematological malignancies | April 12, 2022 1:30 – |
|
2933 | Utility of optical genome mapping for the chromosomal characterization of cell lines used in preclinical and clinical research | April 12, 2022 1:30 – |
“As one company with more solutions, we couldn’t be more excited about participating in AACR. We believe cancer is a disease of structural variation and our OGM and software solutions, which are available for adoption in-house and through our laboratory services, have the potential to make an impact in the fight against cancer. I’m excited for the world to see NxClinical version 6.2 with its innovative capabilities for HRD analysis, as well as our ongoing progress towards our goal of making OGM an essential tool in the arsenal of cancer researchers,” said Erik Holmlin, PhD, president and CEO of Bionano Genomics.
About
Forward-Looking Statements of
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “believe,” “potential,” “goal,” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) convey uncertainty of future events or outcomes and are intended to identify these forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, the the potential contribution of our OGM and software solutions in the fight against cancer and OGM becoming an essential tool for cancer research. Each of these forward-looking statements involves risks and uncertainties. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include the risks and uncertainties associated with: the impact of the COVID-19 pandemic on our business and the global economy; general market conditions; changes in the competitive landscape and the introduction of competitive technologies or improvements in existing technologies; changes in our strategic and commercial plans; our ability to obtain sufficient financing to fund our strategic plans and commercialization efforts; the ability of medical and research institutions to obtain funding to support additional studies, adoption or continued use of our technologies; the ability of our OGM, NxClinical software and laboratory services solutions to offer the anticipated benefits for and contributions to cancer research as well as other areas of research; future study results contradicting the results reported in the presentations given and posters made available at the AACR Annual Meeting; and the risks and uncertainties associated with our business and financial condition in general, including the risks and uncertainties described in our filings with the
CONTACTS
Company Contact:
+1 (858) 888-7610
eholmlin@bionanogenomics.com
Investor Relations:
+1 (858) 366-3243
amy@juniper-point.com
Source: Bionano Genomics